Literature DB >> 8081712

Effects of external cations and mutations in the pore region on C-type inactivation of Shaker potassium channels.

J López-Barneo1, T Hoshi, S H Heinemann, R W Aldrich.   

Abstract

After removal of N-type inactivation in Shaker K channels another inactivation process remains (C-type inactivation). The C-type inactivation time course is reversibly slowed when external [K+] increases. The effect of K+ is mimicked by Rb+ and, with less potency, by the less permeant ions Na+, Cs+, and NH4+. These results, which can be explained by the foot-in-the-door model of gating, could reflect the variable interaction of cations with amino acids in the ion-conducting pore. Mutations at position 449 (near the outer mouth of the pore) produce drastic changes in C-type inactivation kinetics and in its interaction with monovalent cations. Replacement of threonine in the wild-type by glutamic acid or lysine leads to a hundred-fold acceleration of inactivation (time constant approximately 25 ms). In contrast, placing valine at this position results in channels that do not inactivate in 45 s. Moreover, high K+, besides slowing down the inactivation kinetics, produces an increase in current amplitude despite a concomitant decrease in K+ driving force. This second effect, which is larger in mutants with faster inactivation kinetics, is caused by an increase in the number of channels that open on depolarization. Thus, C-type inactivation is a process influenced by the ionic composition of the external milieu which strongly depends on the amino acid at position 449 in the pore region. These findings may help to explain the variability in inactivation kinetics observed in the various types of K channels.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8081712

Source DB:  PubMed          Journal:  Receptors Channels        ISSN: 1060-6823


  348 in total

1.  Barium inhibition of the collapse of the Shaker K(+) conductance in zero K(+).

Authors:  F Gómez-Lagunas
Journal:  Biophys J       Date:  1999-12       Impact factor: 4.033

2.  A small domain in the N terminus of the regulatory alpha-subunit Kv2. 3 modulates Kv2.1 potassium channel gating.

Authors:  M D Chiara; F Monje; A Castellano; J López-Barneo
Journal:  J Neurosci       Date:  1999-08-15       Impact factor: 6.167

3.  UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation.

Authors:  D C Hanson; A Nguyen; R J Mather; H Rauer; K Koch; L E Burgess; J P Rizzi; C B Donovan; M J Bruns; P C Canniff; A C Cunningham; K A Verdries; E Mena; J C Kath; G A Gutman; M D Cahalan; S Grissmer; K G Chandy
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

4.  Regulation of transient Na+ conductance by intra- and extracellular K+ in the human delayed rectifier K+ channel Kv1.5.

Authors:  Z Wang; X Zhang; D Fedida
Journal:  J Physiol       Date:  2000-03-15       Impact factor: 5.182

Review 5.  The dual role of calcium: pore blocker and modulator of gating.

Authors:  R Horn
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  N-type calcium channel inactivation probed by gating-current analysis.

Authors:  L P Jones; C D DeMaria; D T Yue
Journal:  Biophys J       Date:  1999-05       Impact factor: 4.033

7.  Mechanisms of maurotoxin action on Shaker potassium channels.

Authors:  V Avdonin; B Nolan; J M Sabatier; M De Waard; T Hoshi
Journal:  Biophys J       Date:  2000-08       Impact factor: 4.033

8.  U-type inactivation of Kv3.1 and Shaker potassium channels.

Authors:  K G Klemic; G E Kirsch; S W Jones
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

9.  Gating charge immobilization caused by the transition between inactivated states in the Kv1.5 channel.

Authors:  Z Wang; D Fedida
Journal:  Biophys J       Date:  2001-11       Impact factor: 4.033

10.  Inhibition of single Shaker K channels by kappa-conotoxin-PVIIA.

Authors:  David Naranjo
Journal:  Biophys J       Date:  2002-06       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.